SmartLens develops contact lenses for monitoring and treating glaucoma.

SmartLens

Smartlens is a clinical-stage company developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness.

Its flagship product, miLens, is a groundbreaking, non-invasive contact lens-based device designed to monitor intraocular pressure (IOP), the primary and only treatable risk factor for glaucoma. miLens addresses a significant unmet need in glaucoma management that has persisted since the 1950s.

Strong clinical results for miLens were presented at the 2023 and 2024 American Glaucoma Society meetings, and commercialization is planned for 2025.

miLens features a unique, electronics-free sensor technology developed and patented by Smartlens, with protection in over 40 countries. Additionally, the portfolio includes THERmic, an advanced non-invasive drug delivery technology that enhances treatment effectiveness by offering personalized therapies. This technology helps prevent disease progression and lays the foundation for a new generation of therapies.

Smartlens has received investments from prominent institutions, venture capital firms, Stanford University, and key opinion leaders. In recognition of its achievements, Smartlens was honored with the “Outstanding Innovation in Medical Technology and Life Sciences” award at the 2021 High-Tech Awards by Octane. The company’s technologies have also been recognized by prestigious sources such as Nature Medicine, Fortune, BBC, and ABC News.

Smartlens envisions a world where glaucoma no longer robs individuals of their vision and quality of life.

Graphene Ventures

Boutique Venture Partners

Sophia Innovation Capital

Ambit Health Ventures

Device of Tomorrow Capital

Stanford University

WS Investments

Plaisance Capital

3E Bioventures

Smartlens

It was a remarkable experience to speak at the Paving the Path for #Glaucoma's Future panel during the American Glaucoma Society meeting. The Inaugural #Innovation Summit showcased cutting-edge advancements in glaucoma, including Smartlens’ #miLens, enabling #remote IOP monitoring for a more effective approach to managing glaucoma. The overwhelmingly positive feedback, support, and encouragement from numerous glaucoma specialists further validate our efforts to bring miLens to the market. Thank you to everyone who contributed to making this event a great success! Analisa Arosemena, MD Lorraine Provencher Christine Funke Eydie Miller-Ellis Thomas W. Samuelson Gilad Litvin David Esposito Davinder S Grover, MD Deborah Nysather

#innovationinhealthcare #preventblindness #ophthalmology 
#remotepatientmonitoring #glaucomaawareness #earlydiagnosis

Join us at the 2024 AGS Annual Meeting in Huntington Beach, CA, where Smartlens' breakthroughs with miLens, enabling remote IOP monitoring, will be showcased at the Inaugural #Glaucoma Innovation Summit: Paving the Path For Glaucoma's Future, hosted by the American Glaucoma Society.

#remotepatientmonitoring #ophthalmology #innovationinhealthcare 
#preventblindness #personalizedhealthcare  #earlydiagnosis 

https://lnkd.in/eRC97US

Excited to share Smartlens’ progress toward commercialization at #Glaucoma360 by Glaucoma Research Foundation. Join us for an engaging session on Glaucoma Beyond The Office moderated by Drs. Barbara Wirostko MD, FARVO and Lama Al-Aswad, MD, MPH. Reflecting on the insightful discussions from last year's panel on Optimeyezing Eye Care.

#innovationinhealthcare  #preventblindness #eyehealth #glaucoma #personalizedmedicine #ophthalmology #optometry #glaucomaawareness

Thank you, Jennifer Heimlich from Well+Good for an amazing article on the potential of #wearable #devices transforming #healthcare which also showcases the potential of Smartlens’ products. 

As she mentioned, with miLens, those who need it can easily and comfortably check their #eye #pressure a few times a month or year, and ideally catch any changes before #glaucoma progresses to the point where they lose their vision.

Here are some highlights from the article:

- According to a 2023 study from Yale University, more than a quarter of Americans now use a wearable health-tracking device.

- The medical wearables market had an estimated value of $31.06 billion globally in 2023, and is projected to reach $63.68 billion by 2028, according to a July report conducted by market research firm Infogence Global Research. 

-      According to Unity Stoakes, president and co-founder of StartUp Health: “Every device in and around our lives can become a tool to improve our health. Not just the things we wear, like watches, but the cars we drive, the couches we sit on, the pillows we use, the refrigerators where we store our food,” “If today’s most amazing innovators do it right, they will design health into the fabric of our lives.”

Let's embrace this cultural shift towards #proactivehealth and #personalizedmedicine , ensuring a brighter, healthier future for all.

#healthcareinnovation #digitalhealth #wearabletech  #eyehealth     #glaucomaawareness  #preventblindness #ophthalmology #optometry

Smartlens is delighted to announce that our CEO, Savas Komban, will be taking the stage at #Eyecelerator @ AAO 2023, spotlighting the #innovative future of #ophthalmology. Join us in exploring groundbreaking advancements and engaging with industry visionaries driving change. We are committed to contributing meaningful dialogue and are excited to share our latest developments in #EyeCare.

#InnovationInHealthcare #VisionCare #PersonalizedMedicine #PreventBlindness #Glaucoma #EyeHealth

Congratulations to RESI JPM San Francisco Innovator’s Pitch Challenge (IPC) finalist, Smartlens! CEO and Founder, Savas Komban will pitch to a panel of #investor judges, live and in-person, on Tuesday, January 9. Applications are open until 11/22: https://bit.ly/3l4WTKc 
#RESIJPM #RESIJPM24 #RESISANFRAN

Smartlens (#LSIUSA24 Innovator) is aiming to prevent blindness due to Glaucoma and address the biggest challenges in Glaucoma management.

Glaucoma is the leading cause of irreversible blindness worldwide and more than 50% of the people suffering from Glaucoma are undiagnosed.

Smartlens aims to significantly improve patient outcomes and how doctors manage the disease by providing an efficient and convenient way of IOP monitoring and personalized treatments.

The company’s flagship product miLens, is the first device capable of measuring IOP anywhere, at any time. miLens is similar to a daily contact lens and will significantly improve Glaucoma management as a non invasive, electronics free, ultra sensitive, and easy to use device.

🌟 Smartlens recently achieved several major milestones including:

• Announced positive clinical results in a study focused on evaluating the accuracy and comfort of miLens. The study reported a significant and statistically strong correlation between IOP measurements obtained with miLens and those obtained using Goldmann applanation tonometry (GAT) in twenty-five individuals.

• Closed an oversubscribed $6.1M Series A equity financing round led by Ambit Health Ventures, joined by Stanford University, Graphene Ventures, Sophia Innovation Capital, Plaisance Capital Management, 3E Bioventures, Boutique Venture Partners and Wilson Sonsini Investments alongside doctors, industry veterans and key opinion leaders. The funding will be used to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal intraocular pressure

Congratulations to the Smartlens team on these major milestones!

We’re excited to announce that Smartlens CEO, Savas Komban has been selected to present at LSI USA ‘24 in Dana Point, California March 18-22, 2024.

Thank you, Medical Device and Diagnostics, for highlighting Smartlens' dedication to creating user-friendly ophthalmic devices. We believe in harnessing advanced technologies to ensure #exceptional #user #comfort.

The #miLens, our innovative soft contact lens, is designed with a microfluidic system. This allows patients to easily monitor their intraocular pressure from the comfort of their homes, bridging a significant gap in #glaucoma care. 

By intentionally removing electronics from our design, we've created a lens as comfortable and familiar as a corrective contact lens, emphasizing the "Keep It Super Simple" (KISS) approach while solving a significant and unmet medical need. 

As Leonardo Da Vinci wisely said, “Simplicity is the ultimate sophistication”

#innovationinhealthcare  #glaucoma #ophthalmology #preventblindness 
#eyehealth #optometry #medicaldevice #digitalhealth #remotepatientmonitoring 

https://lnkd.in/gJrJ6TZc

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 25, 2024 6:03 PM	8b29ac08
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
peers	general	Aug 25, 2024 6:03 PM	3e1ec1a6
news basic	general	Aug 25, 2024 6:03 PM	667acf84
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

SMAR

HEALTH:SMARTLENS

SmartLens